We are live on ! Find out more

Puma Biotechnology

PBYI

Market cap $471M

9.12 USD

-0.05

0.55%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

9.00

-0.12

1.32%

1 day

-0.55%

5 days

-2.98%

1 month

3.99%

3 months

26.14%

6 months

52%

Year to date

58.06%

1 year

102.67%

5 years

28.45%

10 years

-85.71%

About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Employees: 179

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 58.3%

Negative 8.3%

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.

Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Zacks Investment Research

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

Puma Biotechnology Q2 Earnings Call Highlights

Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million, or $0.07 per share, in the first quarter.

Puma Biotechnology Q2 Earnings Call Highlights

Zacks Investment Research

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.15 per share a year ago.

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotechnology Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its inducement awards granted for July 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™